• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实践参数:新发帕金森病的诊断与预后(循证综述)[已退休]:美国神经病学学会质量标准小组委员会报告

Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology.

作者信息

Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W J

机构信息

University of Calgary, AB, Canada.

出版信息

Neurology. 2006 Apr 11;66(7):968-75. doi: 10.1212/01.wnl.0000215437.80053.d0.

DOI:10.1212/01.wnl.0000215437.80053.d0
PMID:16606907
Abstract

OBJECTIVE

To define key issues in the diagnosis of Parkinson disease (PD), to define features influencing progression, and to make evidence-based recommendations. Two clinical questions were identified: 1) Which clinical features and diagnostic modalities distinguish PD from other parkinsonian syndromes? 2) Which clinical features predict rate of disease progression?

METHODS

Systematic review of the literature was completed. Articles were classified according to a four-tiered level of evidence scheme. Recommendations were based on the evidence.

RESULTS AND CONCLUSIONS

  1. Early falls, poor response to levodopa, symmetry of motor manifestations, lack of tremor, and early autonomic dysfunction are probably useful in distinguishing other parkinsonian syndromes from Parkinson disease (PD). 2. Levodopa or apomorphine challenge and olfactory testing are probably useful in distinguishing PD from other parkinsonian syndromes. 3. Predictive factors for more rapid motor progression, nursing home placement, and shorter survival time include older age at onset of PD, associated comorbidities, presentation with rigidity and bradykinesia, and decreased dopamine responsiveness. Future research into methods for earlier and more accurate diagnosis of the disease and identification and clarification of predictive factors of rapid disease progression is warranted.
摘要

目的

明确帕金森病(PD)诊断中的关键问题,确定影响疾病进展的特征,并提出基于证据的建议。确定了两个临床问题:1)哪些临床特征和诊断方法可将PD与其他帕金森综合征区分开来?2)哪些临床特征可预测疾病进展速度?

方法

完成了对文献的系统综述。文章根据四级证据方案进行分类。建议基于证据得出。

结果与结论

  1. 早期跌倒、对左旋多巴反应不佳、运动表现对称性、无震颤以及早期自主神经功能障碍可能有助于将其他帕金森综合征与帕金森病(PD)区分开来。2. 左旋多巴或阿扑吗啡激发试验以及嗅觉测试可能有助于将PD与其他帕金森综合征区分开来。3. 运动进展更快、入住养老院以及生存时间较短的预测因素包括PD发病时年龄较大、合并症、以强直和运动迟缓为表现以及多巴胺反应性降低。有必要对该疾病的早期和更准确诊断方法以及快速疾病进展预测因素的识别和阐明进行进一步研究。

相似文献

1
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]: report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:新发帕金森病的诊断与预后(循证综述)[已退休]:美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):968-75. doi: 10.1212/01.wnl.0000215437.80053.d0.
2
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病的神经保护策略及替代疗法(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):976-82. doi: 10.1212/01.wnl.0000206363.57955.1b.
3
Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:新发帕金森病的诊断与预后(循证综述):美国神经病学学会质量标准委员会报告
Neurology. 2006 Dec 26;67(12):2266; author reply 2266. doi: 10.1212/01.wnl.0000252726.13187.63.
4
Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病非运动症状的治疗:美国神经病学学会质量标准分会的报告。
Neurology. 2010 Mar 16;74(11):924-31. doi: 10.1212/WNL.0b013e3181d55f24.
5
Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病的神经保护策略及替代疗法(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2007 Jan 9;68(2):164; author reply 164. doi: 10.1212/01.wnl.0000254819.77545.da.
6
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病运动波动和异动症的治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):983-95. doi: 10.1212/01.wnl.0000215250.82576.87.
7
Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:帕金森病抑郁、精神病和痴呆的评估与治疗(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2006 Apr 11;66(7):996-1002. doi: 10.1212/01.wnl.0000215428.46057.3d.
8
Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.实践参数:评估神经病学实践中患者的跌倒风险(循证综述):美国神经病学学会质量标准小组委员会报告
Neurology. 2008 Feb 5;70(6):473-9. doi: 10.1212/01.wnl.0000299085.18976.20.
9
Sniffing out Parkinson disease: can olfactory testing differentiate parkinsonian disorders?嗅出帕金森病:嗅觉测试能否区分帕金森氏症?
Neurologist. 2007 Nov;13(6):382-5. doi: 10.1097/NRL.0b013e31815a351a.
10
EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.EFNS/MDS-ES/ENS [更正] 帕金森病诊断建议。
Eur J Neurol. 2013 Jan;20(1):16-34. doi: 10.1111/ene.12022.

引用本文的文献

1
Integrating Big Data, Artificial Intelligence, and motion analysis for emerging precision medicine applications in Parkinson's Disease.整合大数据、人工智能和运动分析,用于帕金森病新兴的精准医学应用。
J Big Data. 2024;11(1):155. doi: 10.1186/s40537-024-01023-3. Epub 2024 Oct 30.
2
Instrumented timed up and go test and machine learning-based levodopa response evaluation: a pilot study.仪器化定时起立行走测试和基于机器学习的左旋多巴反应评估:一项初步研究。
J Neuroeng Rehabil. 2024 Sep 18;21(1):163. doi: 10.1186/s12984-024-01452-4.
3
Usefulness of Olfactory Bulb Measurement in 3D-FIESTA in Differentiating Parkinson Disease from Atypical Parkinsonism.
嗅球测量在 3D-FIESTA 中鉴别帕金森病与非典型帕金森综合征的作用。
AJNR Am J Neuroradiol. 2024 Aug 9;45(8):1141-1152. doi: 10.3174/ajnr.A8275.
4
Clinical features and neurobiochemical mechanisms of olfactory dysfunction in patients with Parkinson disease.帕金森病患者嗅觉功能障碍的临床特征和神经生化机制。
J Neurol. 2024 Apr;271(4):1959-1972. doi: 10.1007/s00415-023-12122-1. Epub 2023 Dec 27.
5
Tinetti balance performance is associated with mortality in older adults with late-onset Parkinson's disease: a longitudinal study.Tinetti 平衡表现与老年晚发性帕金森病患者的死亡率相关:一项纵向研究。
BMC Geriatr. 2023 Jan 30;23(1):54. doi: 10.1186/s12877-023-03776-7.
6
The Trajectory of Motor Deterioration to Death in Parkinson's Disease.帕金森病运动功能恶化至死亡的轨迹
Front Neurol. 2021 Aug 18;12:670567. doi: 10.3389/fneur.2021.670567. eCollection 2021.
7
Plasma hsa-mir-19b is a potential LevoDopa therapy marker.血浆 hsa-mir-19b 是潜在的左旋多巴治疗标志物。
J Cell Mol Med. 2021 Sep;25(18):8715-8724. doi: 10.1111/jcmm.16827. Epub 2021 Jul 30.
8
Computational medication regimen for Parkinson's disease using reinforcement learning.基于强化学习的帕金森病药物治疗方案计算。
Sci Rep. 2021 Apr 29;11(1):9313. doi: 10.1038/s41598-021-88619-4.
9
Gradient boosting for Parkinson's disease diagnosis from voice recordings.基于语音记录的梯度提升算法用于帕金森病诊断
BMC Med Inform Decis Mak. 2020 Sep 15;20(1):228. doi: 10.1186/s12911-020-01250-7.
10
Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson's Disease.中脑的血管周围间隙增宽可能反映帕金森病中的多巴胺能神经元变性。
Front Aging Neurosci. 2020 Jun 5;12:161. doi: 10.3389/fnagi.2020.00161. eCollection 2020.